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Abstract
Despite new additions to the standard of care therapy for high grade primary malignant brain tumors, the prog-
nosis for patients with this disease is still poor. A small contingent of clinical researchers are focusing their efforts
on testing the safety, feasibility and efficacy of experimental active and passive immunotherapy approaches for
gliomas and are primarily conducting Phase I and II clinical trials. Few trials have advanced to the Phase III arena.
Here we provide an overview of the cellular therapies and vaccine trials currently open for patient accrual obtained
from a search of http://www.clinicaltrials.gov. The search was refined with terms that would identify the Phase I, II
and III immunotherapy trials open for adult glioma patient accrual in the United States. From the list, those that
are currently open for patient accrual are discussed in this review. A variety of adoptive immunotherapy trials using
ex vivo activated effector cell preparations, cell-based and non-cell-based vaccines, and several combination passive
and active immunotherapy approaches are discussed.
Introduction
The majority of primary tumors of the central nervous
system (CNS) are of astrocytic lineage [1]. Glial tumors
are typically classified based upon histologic criteria.
The World Health Organization (WHO) classification
system for primary malignant gliomas in adults has
g r a d i n g st h a tr a n g ef r o mI It oI V .T h em o r es l o w l y
growing WHO grade II tumors are termed astrocytomas
(A), oligodendrogliomas (ODG), or mixed gliomas
(MG). WHO grade III tumors are similarly designated
but with the word anaplastic preceding the names, i.e.,
anaplastic astrocytomas (AA), anaplastic oligodendro-
gliomas (AODG) or mixed anaplastic gliomas (MAG).
The most malignant form, a WHO grade IV glioma is
termed a glioblastoma or glioblastoma multiforme
(GBM). GBMs are diagnosed at a much higher fre-
quency than the lower grade astrocytomas. Recent GBM
groupings– classified as proneural, mesenchymal, neuro-
nal, or classical– reflect genetic features of the tumor
and have prognostic significance [2,3].
Even with new aggressive standard of care upfront
radio-chemotherapy (http://www.clinicaltrials.gov,
NCT00006353) [4], the overall survival of GBM patients
at two years is dismal at 27.2% [5]. Adjuvant experimen-
tal therapies to follow surgical resection and radio-che-
motherapy are being explor e d ,a m o n g s tt h e mp a s s i v e
and active immunotherapies. Comparing our reviews on
immunotherapeutic approaches for brain tumors that
were published nearly 10 years ago [6,7] to the present,
two obvious changes to the field are evident. First, trials
employing active immunotherapy now outnumber those
involving passive immunotherapy, and second, investiga-
tors are more routinely testing various immune
approaches with glioma patients before they exhibit
tumor recurrence.
We provide a synopsis of the individual active and
passive immunotherapy trials and those that use com-
bined active and passive approaches. Three tables sum-
marize the information to include treatment site(s) and
lead investigator, an abbreviated trial description, the
study phase and estimated enrollment, and indication of
whether eligible patients must have recurrent (R), persis-
tent (P) or newly diagnosed (ND) brain tumors at a par-
ticular malignant stage (WHO grade). Figure 1
illustrates the geographic distribution of the immu-
notherapy trials in the United States.
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T h ea d o p t i v et r a n s f e ro fex vivo activated cytotoxic
effector cells to the patient is categorized as a form of
passive immunotherapy. The effector cells are adminis-
tered either systemically or intracranially. If placed intra-
tumorally, the effector cells may be either autologous or
allogeneic to the patient. The types of effector cells
tested include cytotoxic T lymphocytes (CTL) that are
specifically-sensitized to glioma associated antigens
(GAA) and exhibit human leukocyte antigen (HLA)
restriction [8]. Alternatively, natural killer (NK) or lym-
phokine activated killer (LAK) cells have been used that
are HLA-non-restricted [6,7].
Currently, there are five clinical trials evaluating the
safety and effectiveness of cellular therapy approaches
(Table 1). At The City of Hope (Duarte, CA), the per-
ipheral blood mononuclear cells (PBMC) from the blood
of healthy allogeneic donors are being genetically modi-
fied to express a chimeric T cell receptor (TCR) that
targets the Interleukin-13 receptor a2 (IL-13Ra2) with a
membrane tethered fusion protein known as the IL-13-
CD3ζ zetakine (NCT01082926) [9,10]. The zetakine has
an E13Y mutation conferring exceptional affinity to the
IL-13Ra2 molecule, and reduced affinity to the more
commonly expressed IL-13Ra1 .S i n c en e a r l y8 0 %o f
high grade primary brain tumors express IL-13Ra2, but
normal brain cells do not, the effector cells target the
glioma cells [11-14]. Delivery of the gene-modified allo-
geneic T cells given with aldesleukin (IL-2) for newly-
diagnosed patients with WHO grade III or IV brain
tumors is by convection enhanced delivery (CED). Con-
current dexamethasone is allowed. The T cell transfec-
tants also express hygromycin phosphotransferase-
Herpes simplex virus (HSV) thymidine kinase suicide
gene (HyTK) under the control of the cytomegalovirus
(CMV) immediate early promoter to provide a method
for ablation if graft versus host disease or autoimmunity
should occur [9].
Two other clinical trials, one at Baylor College of
Medicine (NCT01109095) and another at Penn State
University (NCT00990496), evaluate the safety and
patient response to intravenous adoptive transfer with
autologous or allogeneic CTL, respectively. The CTL
target the highly immunogenic human b-herpes cytome-
galovirus (hCMV) specific antigens that have been
shown to be associated with ~70-90% of glioma cells
but not normal brain [15-17]. The CTL for the Baylor
trial are additionally gene modified to target HER2, an
antigen expressed by nearly 80% of GBMs [18,19]. In
this dose escalation trial newly diagnosed GBM patients
are treated with one intravenous injection of autologous
HER-CMV-CTL. In the Pennsylvania State Phase I/II
trial, recurrent or refractory/progressive GBM patients
undergo single dose total body irradiation and three
Figure 1 Map of the United States showing geographical locations of immunotherapy clinical trials discussed in the review. States
shaded in gray have immune therapy clinical trials that are open and currently accruing patients. The city locations of one or more cellular
therapy trials are indicated with a blue star, the vaccine therapy trials with a red circle, and the combined cellular and vaccine therapy trials with
a white triangle.
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eliminate immunosuppressive T regulatory cells (Treg)
before receiving intravenous infusion of the allogeneic
CMV-specific CTL [20].
A dose escalation trial involving intratumoral adoptive
transfer of alloreactive CTL (alloCTL) is open for
accrual of recurrent glioma patients at the University of
California, Los Angeles (UCLA, NCT01144247). After
surgical debulking, alloCTL will be placed in the resec-
tion cavity. Later alloCTL infusions are delivered
through a subgaleal Rickham reservoir/catheter placed
at the time of surgery. Patients are treated with 2
alloCTL infusions, 7 days apart to complete 1 cycle. Up
to 5 treatment cycles are possible and given every other
month. The alloCTL are derived from different donors
at each cycle who are allogeneic to the patient. The
effector alloCTL are trained ex vivo to recognize patient
HLA that is highly expressed on the surface of glioma
cells but is not present on normal neurons or glia. The
trial is predicated upon the results of an earlier pilot
study where 3 of 6 recurrent malignant glioma patients
demonstrated benefit [21]. One patient survived 40
months, and the remaining two are alive >15 years from
the start of immune therapy and entrance into protocol.
At Hoag Cancer Center (Newport Beach, CA), an
open, randomized double arm Phase II clinical trial is
evaluating the safety of single dose intracavitary autolo-
gous LAK cells. This is being compared to Gliadel wafer
in newly diagnosed GBM patients (NCT00814593). LAK
cells are generated when the patient’sP B M Ca r ec u l -
tured with high dose recombinant human IL-2 [22].
Cell Based Vaccine Therapy Trials
Immunization of patients relies upon activation of endo-
genous immune cells and is categorized as a form of
active immunotherapy. In Table 2 (upper half) we list 4
cell-based vaccination trials. Three of the 4 use an auto-
logous dendritic cell (DC) approach to activate the
patient’s immune system, while 1 uses irradiated autolo-
gous whole tumor cells. Another 5 trials (Table 2, lower
half) are non-cell based vaccines that employ GAA pep-
tides or complexes that may be combined with
immune-potentiating adjuvants. In some cases these
therapies will be delivered with other chemotherapeutic
agents such as temozolomide (TMZ), or bis-chloroethyl-
nitrosourea (BCNU) or the monoclonal antibody dacli-
zumab which binds to the high affinity alpha subunit
(p55 aka CD25) of the IL-2 receptor.
The ongoing Phase I dose-escalation trial at UCLA
(NCT00068510) involves DC that are pulsed with auto-
logous tumor cell lysates. The primary endpoint is to
evaluate dose limiting toxicity and the maximum toler-
ated dose of tumor cell lysate pulsed DC in patients
with newly diagnosed and recurrent gliomas. Patient
response was seen previously when patients received DC
pulsed with acid-eluted peptides or tumor lysate admi-
nistered in combination with chemotherapeutic agents
[23,24].
Another variation of the DC vaccine approach is being
tested at Cedars-Sinai in Los Angeles (NCT00576641)
and is enrolling recurrent WHO grade IV or brain stem
gliomas. The approach offers patients with tumor
located in unresectable locations an opportunity to
receive adjuvant immune therapy. Enrollment into this
clinical trial is restricted to patients who are HLA Class
I A1 or A2 positive since the synthetic peptides used to
pulse the DC are from GAA that display HLA-A1 or
-A2 restrictions. Other vaccine trials at Cedars-Sinai
(NCT00576537, NCT00576446) using DC pulsed with
autologous tumor cell lysates with or without intratu-
moral Gliadel wafer recently were closed for accrual.
At Duke University (NCT00890032), recurrent GBM
patients are treated with autologous DC that are pulsed
with mRNA isolated from autologous CD133+ brain
tumor stem cells. The method of using mRNA isolated
from the patient’s own tumor cells to pulse their DC
Table 1 Cellular Therapies for Glioma Patients
Center/Investigator Therapy/Protocol Phase -
Enrollment
ND,
P, R*
WHO
Grade***
Clinicaltrials.gov
identifier
References
City of Hope, Duarte, CA/B Badie Allogeneic T Cells modified with chimeric
IL-13a2 - TCRζ
I - 10 R, P III or IV NCT01082926 Kahlon et al
[9]
Baylor College of Medicine,
Houston, TX/N Ahmed
Autologous CMV specific CTL genetically
modified to target Her2
I/II - 18 ND IV NCT01109095 Ahmed et al
[18]
Penn State University, Hershey,
PA/K Lucas
Allogeneic, CMV specific CTL I/II - 10 R IV NCT00990496 Bao et al
[20,72]
UCLA, Los Angeles, CA/L Liau Alloreactive CTL and IL-2 1 - 15 R III NCT01144247 Kruse &
Rubinstein [21]
Hoag Cancer Center, Newport
Beach, CA/R Dillman
Autologous LAK Cells II - 80 ND IV NCT00814593 Dillman et al
[22,73]
* ND, Newly Diagnosed; P, Persistent; R, Recurrent
** World Health Organization (WHO) Grade III: AA, AODG; Grade IV: GBM
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in vitro study using human glioma tissue and autologous
PBMC [25,26].
Last, at Massachusetts General/Dana Farber Cancer
Institute (NCT00694330) a vaccine comprised of irra-
diated autologous whole tumor cells are given along
with K562 cells engineered to produce granulocyte-
macrophage colony stimulating factor (GM-CSF), theo-
retically as a constant source of immune-adjuvant cyto-
kine [27]. Since the K562 erythroleukemic cells, derived
from a patient with chronic myelogenous leukemia,
express tumor associated antigens such as survivin,
hTERT, and Mage-1 in common with gliomas
[19,28-31], they also may serve as an additional source
of GAA peptides for DC uptake.
Non-cell-based Vaccine Trials
The lower half of Table 2 summarizes the 5 open non-
cell-based vaccine trials currently accruing patients. The
first is a Phase I/II trial at Duke University
(NCT00626015) that employs a EGFRviii directed-pep-
tide (CDX-110) vaccine that is given intradermally to
treat newly diagnosed GBM patients. The EGFRviii var-
iant of EGFR is expressed by nearly a third of glioma
specimens [32] therefore the patients enrolled must
exhibit positivity for the antigen. The vaccine is admi-
nistered in conjunction with standard of care TMZ after
completion of radio-chemo-therapy. In one arm of the
trial patients also receive the anti-IL-2Ra (daclizumab),
since Treg cells are more sensitive to that antibody com-
pared to the cytotoxic T cell counterpart. Intradermal
injections of CDX-110 peptide, or peptide loaded DC
has led to increased overall survival in clinical trials
without reported autoimmunity [33].
Two Phase 0 clinical trials open at Pittsburgh Cancer
Center (NCT00874861, NCT00795457) are evaluating
subcutaneous immunization with GAA peptides (IL-
13Ra2, Survivin, EphA2 and WT1-derived peptides) and
1 or 2 adjuvants. The first adjuvant is polyinosinic-poly-
cytidylic acid stabilized with polylysine and carboxy-
methylcellulose (poly-ICLC) that acts as a Toll like
receptor 3 agonist and is given intramuscularly 8 times
3 weeks apart. The second adjuvant is Montanide ISA-
51, a water-in-oil emulsion that is also given intramus-
cularly as an immune modulating agent [34]. HLA-A2
positive glioma patients with recurrent grade II tumors
are being enrolled.
Two more vaccine trials are open at University of
California, San Francisco for recurrent (NCT00293423)
or newly diagnosed (NCT00905060) patients with GBM.
Enrolled patients are being vaccinated with the heat
shock protein peptide complex (HSPPC)-96 with or
without concurrent TMZ therapy. Heat shock proteins
(HSP) are highly conserved proteins that are transiently
expressed during cell stress. They function as molecular
chaperones and in the proper folding, assembly, and
transport of nascent peptides, and in the degradation of
misfolded peptides. Some HSP are highly upregulated
Table 2 Vaccine Trials for Glioma Patients
Center/Investigator Therapy/Protocol Phase -
Enrollment
ND,
P, R*
WHO
Grade **
Clinicaltrials.
gov identifier
References
Cell-Based Vaccines
UCLA, Los Angeles, CA/L Liau Autologous DC + Tumor Lysate I - 36 ND III or IV NCT00068510 Liau et al [46]
Cedars-Sinai, Los Angeles, CA/S
Phuphanich
Autologous DC + Synthetic Glioma
Peptide
I - 39 R, P IV NCT00576641 ***
Duke Univ, Durham, NC/D Mitchell Autologous DC + Brain Tumor Stem
Cell-mRNA
I - 50 R IV NCT00890032
Mass General, Boston, MA/W Curry
Dana Farber, Boston, MA/P Wen
Autologous Tumor Cells + Irradiated
GM-CSF Producing K562 Cells
I - 25 R III or IV NCT00694330
Non-cell Based Vaccines
Duke Univ, Durham, NC/D Mitchell CDX-110 (EGFRviii) Peptide Conjugate +
TMZ ± Daclizumab
I/II - 20 ND IV NCT00626015 Heimberger
et al [74]
Pittsburgh Cancer Center, Pittsburgh,
PA/F Lieberman
GAA peptides + PolyICLC 0 - 9 R II NCT00874861 Butowski et
al [75] ****
Pittsburgh Cancer Center, Pittsburgh,
PA/F Lieberman
GAA/TT-peptides + PolyICLC +
Montanide ISA-51
0-6 R II NCT00795457
UCSF, San Francisco, CA/A Parsa Autologous HSPPC-96 vaccine I/II - 50 R IV NCT00293423 Yang & Parsa
[76]
UCSF, San Francisco, CA/A Parsa Autologous HSPPC-96 ± TMZ II - 63 ND IV NCT00905060
* ND, Newly Diagnosed; P, Persistent; R, Recurrent
** WHO Grade II: A, ODG, MG; Grade III: AA, AODG, MAG; Grade IV: GBM.
*** GAA peptides include: HER-2, TRP-2, gp100, MAGE-1, IL13R alpha, and AIM-2; patients with Brain Stem Glioma are eligible for enrollment
****GAA peptides include: IL-13Ralpha2, Survivin, EphA2 and WT1-derived peptides; GAA/TT includes helper peptide derived from tetanus toxoid
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HSP non-covalently binds to tumor antigens present in
the patient’s own tumor forming an immunogenic com-
plex that is capable of activating CTL, but neither the
gp-96, nor the tumor antigen is immunogenic on its
own [37,38].
Combination Cellular and Vaccine Immunotherapy Trials
Four trials have complex treatment strategies that
employ combined active and passive approaches for
patients with brain tumors (Table 3). Three currently
open clinical trials at Duke University (NCT00639639,
NCT00693095, NCT00627224) employ either intrader-
mal vaccination with CMV-specific DCs or CMV-speci-
fic autologous lymphocyte transfer (ALT), or both, for
newly diagnosed GBM patients. Adoptively transferred
CMV-specific CTL reconstitute the hematopoietic sys-
tem following TMZ-induced lymphopenia that selec-
tively depletes Treg cells, and CMV-specific CTL.
The first trial (NCT00639639) is randomized into 4
arms that evaluate a) CMV-DCs with CMV-ALT, b)
CMV-DC alone, c) radiolabeled CMV-DCs following
unpulsed DC administration, and d) radiolabeled CMV-
DCs following skin site preparations with tetanus toxin.
The CMV-specific DCs are pulsed with the pp65-lysoso-
mal-associated membrane protein (LAMP) mRNA and
given 3 times. For CMV-ALT, autologous pp65-specific
CTL are given once intravenously. The second trial
(NCT00693095) involves patient treatment with CMV-
ALT with or without CMV-DCs pulsed with pp65
mRNA. Patients will also receive standard of care radio-
therapy and TMZ. Interestingly, patients whose tumor
recurs following experimental therapy will be offered a
resection of the intracavitary tissue with intracranial pla-
cement of radiolabeled CMV-DC. The third trial
(NCT00627224) similar to the first has four arms: a)
CMV-ALT with CMV-DC, b) CMV-ALT alone, c) radi-
olabeled CMV-DC, and d) radiolabeled CMV-DC that
are pulsed with mRNA for the CC chemokine receptor
7( C C R 7 )i na ne f f o r tt od i r e c tt h eC M V - s p e c i f i cD Ct o
the lymph nodes. Upon recurrence, biopsies will be eval-
uated for DC or CTL infiltrates, and for pp65-antigen
escape.
Finally, an open Phase I/II trial at St. Lukes Hospital
(Kansas City, MO) combines active and passive immune
strategies in patients with recurrent grade III or IV
glioma (NCT01081223). Patients are immunized with
irradiated autologous tumor cells and GM-CSF (TVAX).
Later, autologous T cells are harvested and expanded ex
vivo, and then administered intravenously. Pilot clinical
trials showed promising results with this approach to
expand autologous anti-tumor CTL [39]. A similar strat-
egy was employed in two Phase II trials that are either
active but not recruiting (NCT00003185) or closed
(NCT00004024) [40-42].
Perspectives On Current Status Of The Field And Future
Directions
Six states have immunotherapy trials open for patient
enrollment at present with a strong contingency of
investigators conducting immune therapy trials concen-
trated on the west coast of the United States (Figure 1).
Comparing these results to reviews that we published
nearly a decade ago [6,7] it appears that the overall
number of open trials is encouragingly higher. However,
while the number of cellular therapy trials remained the
same, the clear trend was towards an increase in the
number of vaccine trials. Perhaps the costs and the
complex logistics associated with generating effector
cells for cellular therapy trials influenced this trend.
Commonly, Phase I dose-escalation studies in stan-
dard 3+3 design are conducted to ensure safety at any
given dose before randomized studies focusing on a par-
ticular dose level are initiated. In small Phase 0 and I
trials, some now using creative designs with as few as 6-
15 patients per arm (see Tables) where toxicity is the
primary concern, the likelihood of variability in treat-
ment outcome, especially when they are receiving differ-
ent doses, is high. Therefore, the studies are
underpowered to make robust correlations between
Table 3 Combined Active and Passive Immunotherapies for Glioma Patients
Center/Investigator Therapy/Protocol Phase/
Enrollment
Number
ND,
P, R*
WHO
Grade**
Clinicaltrials.
gov identifier
References
Duke Univ, Durham, NC/
D Mitchell
CMV-DCs ± CMV-ALT + TMZ ± Skin site
preparation (unpulsed DC or tetanus toxoid)
I/II - 16 ND IV NCT00639639 Mitchell et
al [16,77]
Duke Univ, Durham, NC/
D Mitchell
CMV-ALT ± CMV-DCs + RT + TMZ (intratumoral
CMV-DC upon recurrence)
I - 12 ND IV NCT00693095 Mitchell et
al [16,77]
Duke Univ, Durham, NC/
D Mitchell
CMV-ALT ± CMV-DC or CMV-DC ± CCR7-DC I/II - 20 ND IV NCT00627224 Mitchell et
al [16,77]
St. Lukes Hosp, Kansas
City, MO/M Salacz
Autologous Tumor Cells + GM-CSF ® iv Activated
T Cells + IL-2 (TVAX)
I/II - 10 R III or IV NCT01081223 Wood et al
[39]
* ND, Newly Diagnosed; P, Persistent; R, Recurrent
** WHO Grade III: AA, AODG; Grade IV: GBM
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ated. Furthermore, there are challenges in making com-
parative assessments between individual trials. The
patient populations treated must be segregated into uni-
form groups for data analysis. For valid statistical con-
clusions to be reached one cannot directly compare the
outcomes of two individual trials where in one the
patients enrolled have persistent or recurrent tumors,
and in the other, only recurrent tumors.
Although promising yet anecdotal results have been
documented in brain tumor patients treated with a vari-
ety of immunotherapeutic approaches [21,43-46] few
have advanced from the Phase I/II experimental stage to
Phase III testing, testimony of the small number of
groups with a research focus in immunotherapy and the
constraints placed on NIH for funding such trials
because of the current financial climate. Importantly,
data gathered from these pilot studies do highlight cer-
tain factors that affect response to therapy such as age,
maximal resection or minimal/stable residual disease at
the start of vaccine therapy, and concurrent administra-
tion of chemotherapeutics [23,24,46-51]. For valid con-
clusions to be reached timely about the value of these
approaches more patient participation will be required.
Also, with recent advances in new computer-guided sur-
gical techniques, radiation protocols and chemotherapy
agents, replacement of older historical control groups
with newer ones will be required. With the introduction
of new therapies to standard of care for gliomas (i.e.,
temozolomide, bevacizumab), immunotherapy trials
must engender improved survival and quality of life to
become integrated into the standard of care regime
[5,52-54].
The number of slots open for patient accrual to the
immunotherapy protocols contained in our list of open
trials totals 489. Based upon the 2010 CBTRUS estima-
tions that 18,980 patients will be diagnosed with a
glioma this year in the United States [1], if all available
slots were filled in a year, a highly unlikely event, it still
would represent only 2.6% participation by the patients
in experimental immune testing. Movement toward
Phase III trials is encouragingly on the horizon. The lar-
gest clinical trial investigating the use of DC vaccines to
treat patients with brain tumors (DCVax®-Brain) is
sponsored by Northwest Biotherapeutics. Although no
longer recruiting patients, there are currently 12 institu-
tions participating in the conduct of the Phase II study
that is completing treatment and follow-up of 141
enrolled patients http://clinicaltrials.gov/ct2/show/
record/NCT00045968[55]. The patients who were trea-
ted on the Phase I clinical trials, from which the Phase
II study testing DCVax®-Brain is predicated, encoura-
gingly continue to demonstrate delays in disease pro-
gression and extensions in overall survival http://www.
nwbio.com/clinical_dcvax_brain.php[56]. Also, Celldex
Therapeutics http://www.celldextherapeutics.com/[57]
has plans to conduct a Phase III trial to test EGFRvIII
peptide vaccination if the results of their Phase II multi-
institutional trial conducted at sites in 15 states http://
clinicaltrials.gov/ct2/show/study/NCT00458601 is suc-
cessful [58,33]. Interim positive results from a Phase 2b
brain cancer study with CDX-110, a non-cell based vac-
cine using an EGFRviii peptide conjugate, given with
TMZ were just presented at the 46th Annual ASCO
Meeting http://ir.celldextherapeutics.com/phoenix.
zhtml?c=93243&p=irol-newsArticle&ID=1434902&high-
light=[59]. In addition, ImmunoCellular Therapeutics,
Ltd http://www.imuc.com/[60] reports from a recent
Phase I study of ICT-107, a DC-based vaccine targeting
multiple GAA, that the median overall survival had not
yet been reached in patients at the 26.4 month analysis
point, with 12 out of 16 treated newly diagnosed GBM
patients alive. The company is planning to initiate a
phase II study of this vaccine at 15 clinical sites in the
second half of 2010 http://www.tradingmarkets.com/
news/stock-alert/avrod_imuc_immunocellular-therapeu-
tics-signs-agreement-with-averion-international-to-con-
duct-phase-ii-glioblast-1176363.html[61]. Finally,
Antigenics, Inc. http://www.antigenics.com[62] is sup-
porting a Phase II multi-center single-arm, open-label
study to evaluate response to vaccine treatment with
Oncophage. Data from 32 evaluable patients treated at
UCSF indicate an overall median survival of 44 weeks
after tumor resection was achieved, with ~70% of the
evaluable patients surviving >36 weeks, and 41% surviv-
ing one year or longer. It is clear that clinical trials that
address efficacy have been furthered because of support
by the biotechnology sector. However, for certain
immune therapy products, especially personalized med-
icinal products produced for diseases with orphan status
where the market is small, accompanying support by the
National Institutes of Health will be critical.
Furthermore, standardization of the immunologic
monitoring endpoints would also help advance the
immunotherapy field. Centralized immunologic moni-
toring laboratories could offer uniform sample handling
and analysis. Common endpoints could more reliably
provide better comparisons between the individual pro-
tocols. Patient responses to immune treatments are
assessed over time in cytotoxicity assays by increases in
GAA-specific CTL or GAA tetramer analysis in the
patients PBMC. Other measurements have included
qPCR or Elispot for T helper 1 cytokines, such as IFN-g,
appearance or increases of phenotypically defined cyto-
toxic subsets in PBMC upon exposure to relevant target
cells, and for vaccines in particular, lymphocytic infil-
trates at biopsied vaccination sites or tumor site [63-67].
Since it has been noted that patient response to
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laboratory endpoints [46], better definition in this area
is needed. Additionally, immunoresistance and genetic
variation following immunotherapy could be monitored
to address reasons for nonresponse or recurrence [68].
Adjuvant experimental immune therapies are more
likely to be of benefit for treating the smaller number of
tumor cells remaining after surgical resection. Tumor
resection provides an advantage for immune therapies
as it helps to reduce the level of immunosuppressive
factors produced and secreted by the tumor cells, such
as transforming growth factor-beta (TGF-b)o rp r o s t a -
glandin-E2 [69,70]. When the tumor volume is large
immunosuppressive factors can be high locally within
the tumor microenvironment, and as well, systemically.
Overall, surgical resection will have the effect of redu-
cing the number of tumor infiltrating Treg cells or mye-
loid-derived suppressor cells that also can produce
immunosuppressive or T helper (Th) 2 or Th3 cytokines
such as IL-10 or TGF-b, respectively [68].
Should the single or combined immune therapy mod-
alities be ineffective, combining active or passive immu-
notherapy approaches with other gene therapy
approaches may come to fruition. For instance, our
group is currently exploring the possibility of combining
alloCTL cellular therapy, now being tested individually
(NCT01144247), with gene therapy employing replica-
tion competent retroviral vectors encoding suicide genes
(NCT01156584), also now being tested individually
[71,72]. The combined approaches may not only prove
useful for primary malignant brain tumors http://projec-
treporter.nih.gov/project_info_description.cfm?
aid=7746420&icde=4191938[73], but for tumors meta-
static to the brain.
Finally, besides contrast-enhanced magnetic resonance
imaging (MRI) scans for following brain tumor patient
response to immune therapy, other tests should be fac-
tored in with those assessments. It is difficult to differ-
entiate inflammation from tumor progression, as both
result in enhancement on scans. Follow-up using this
one assessment modality has resulted in premature pla-
cement of patients off protocol. New experimental MRI
and positron emission tomography (PET) techniques are
becoming available to help make these assessments and
distinguish between pseudo-progression and true tumor
progression [74,75]. If validated, the techniques concei-
vably could be used in conjunction with other less
expensive tests to help provide this information. For
example, since tumor cells themselves produce and
secrete immunosuppressive factors, such as TGF-b,w e
suggest that serum measurements of TGF-b may be
monitored over time as a measure of tumor burden. Its
increase systemically, after surgical resection, could offer
an indication of tumor regrowth.
Conclusions
To refine the searches on clinicaltrials.gov we included
the following terms: glioma and biotherapy or immu-
notherapy, autologous, allogeneic, and vaccine; we limited
the search to trials enrolling adult patients and asked for
all Phase I, II and III trials in the United States.O ft h e
listed trials, we focused on those employing cellular ther-
apy, DC or peptide-based vaccines, or combined
approaches. Overall, we are encouraged by the advances
this field has seen in the last decade. A welcome prece-
dence, the FDA recently approved PROVENGE®, a den-
dritic cell-based vaccine made by Dendreon Corporation
http://www.dendreon.com for metastatic, hormone-
refractory prostate cancer [76-78]. We look forward to
the time when gathered evidence provides implementa-
tion of immunotherapeutic approaches to gliomas not
only as standard of care, but as first-in-line treatment
options. To timelier advance these possibilities, we pro-
pose the formation of immunotherapy consortiums that
could provide the administrative and statistical oversight
and immunologic endpoint integration needed and
encourage cooperation between the small cohorts of
investigators working in the immune therapy arena. By
doing so, integration of novel cellular and vaccine treat-
ments as part of the treatment armamentarium for
glioma patients may soon be realized.
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